Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   Bio Blast Pharma (ORPN)

Amerikaanse aandelen« Terug naar discussie overzicht

Bio Blast Pharma (ORPN)

Volgen
70 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  10. I Love Melbourne 19 juni 2016 13:18
    Bioblast Pharma Ltd. (Nasdaq: ORPN) announced that it plans to initiate a Phase 2b trial with trehalose IV solution in OPMD during the second half of 2016, and has commenced a scientific and business assessment to determine the suitability of using trehalose IV solution in other orphan diseases.

    The company intends to enroll more than 70 patients in the Phase 2b clinical trial at up to 15 sites in the United States and Canada. This double-blind, placebo-controlled trial follows from the HOPEMD open label Phase 2a study in which trehalose IV solution was observed to be safe and well tolerated, with no drug-related serious adverse events. Additionally, improvements versus baseline were observed in multiple efficacy endpoints related to dysphagia and muscle strength and function.

    “Given the interest in the scientific and medical community with regard to alternative therapeutic uses of trehalose, we have decided to concentrate our internal development efforts exclusively on this drug candidate, which will enable us to leverage our extensive knowledge and expertise from our R&D and manufacturing efforts,” stated Fredric Price, Bioblast’s Executive Chairman. “In the event that we determine to investigate other diseases for which trehalose IV solution may provide positive disease modifying outcomes, we anticipate that we will be able to enter into additional Phase 2 programs rapidly and with little or no incremental preclinical expenses. We anticipate providing shareholders with more information on this expanded trehalose IV solution development program later this year. With this change in mind, we have chosen to postpone work on the mitochondrial replacement and read-through platforms."

    “Consequently, with our focus on trehalose IV solution, we have made the decision to streamline company expenditures and downsize the management team, with the result being, among other things, that up to 8 employees have left or will be leaving Bioblast, including the Chief Commercial Officer, Chief Corporate Development Officer, and Chief Financial Officer. Additionally, Colin Foster, Bioblast’s President and CEO, will be leaving his operational position but will continue as a member of the Board of Directors,” continued Mr. Price. “I will remain in my role as Executive Chairman and will lead the Company’s day-to-day operational efforts starting July 1, 2016. Commitments for the payment of severance and related benefits in connection with the personnel adjustments of approximately $1.7 million are expected to be substantially paid out during the third quarter of 2016. The savings from this streamlining are expected to be realized beginning in 2017.”

    Bioblast ended the first quarter of 2016 with $21.6 million in cash and equivalents.

    “I would like to express my gratitude to those members of our Bioblast team affected by this downsizing,” said Mr. Foster. “These employees have worked with dedication and passion and we are grateful and proud of the work they have done. I am confident that the core remaining operational team, under Fred’s leadership has the skills necessary to drive the trehalose programs forward.”

    “I am gratified that Colin will remain on the Board of Directors and want to thank him for his extraordinary service to the Company in an operational capacity,” said Mr. Price. “His advice and counsel are invaluable to the Board and me, and I look forward to working with him closely as we move the Company forward.”

    www.streetinsider.com/Corporate+News/... (9-6-2016)
70 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Alfen N.V. 13,550 +2,17 +19,07%
ArcelorMittal 24,630 +1,50 +6,49%
FASTNED 22,250 +1,30 +6,21%
AALBERTS NV 35,140 +2,04 +6,16%
JUST EAT TAKEAWAY 11,180 +0,62 +5,87%
BESI 108,800 +5,70 +5,53%
Pharming 0,758 +0,03 +4,63%
THEON INTERNAT 9,190 +0,39 +4,43%
Fugro 17,200 +0,65 +3,93%
Aperam 25,940 +0,92 +3,68%
Philips Koninklijke 25,500 +0,85 +3,45%
Vopak 42,660 +1,28 +3,09%
NX FILTRATION 4,605 +0,14 +3,02%
TomTom 5,280 +0,14 +2,62%
ASMI 511,600 +12,80 +2,57%
EXOR NV 95,550 +2,20 +2,36%
ASML 624,700 +13,90 +2,28%
Sif Holding 13,380 +0,28 +2,14%
SBM Offshore 17,530 +0,35 +2,04%
HEIJMANS KON 25,100 +0,50 +2,03%
RANDSTAD NV 43,520 +0,84 +1,97%
WDP 20,980 +0,38 +1,84%
RENEWI 7,390 +0,13 +1,79%
ALLFUNDS GROUP 5,570 +0,10 +1,74%
PROSUS 39,455 +0,60 +1,56%
AMX 868,76 +13,15 +1,54%
INPOST 17,950 +0,26 +1,47%
ABN AMRO BANK N.V. 15,325 +0,19 +1,29%
Aegon 6,236 +0,07 +1,20%
Galapagos 25,540 +0,30 +1,19%
Basic-Fit 22,740 +0,26 +1,16%
B&S Group SA 4,500 +0,05 +1,12%
Eurocommercial Properties 23,150 +0,25 +1,09%
Flow Traders 21,600 +0,22 +1,03%
Heineken 72,940 +0,74 +1,02%
Brunel 8,960 +0,09 +1,01%
SIGNIFY NV 22,040 +0,20 +0,92%
Arcadis 65,150 +0,55 +0,85%
Corbion 22,580 +0,18 +0,80%
UMG 23,250 +0,18 +0,78%
Sligro 11,180 +0,08 +0,72%
Akzo Nobel 59,400 +0,42 +0,71%
Accsys 0,604 +0,00 +0,67%
AZERION 1,296 +0,01 +0,62%
SHELL PLC 31,615 +0,18 +0,59%
ASCX 1.199,83 +6,67 +0,56%
Fagron 18,800 +0,10 +0,53%
Van Lanschot Kempen NV 41,850 +0,20 +0,48%
ACOMO 17,320 +0,08 +0,46%
NSI 19,480 +0,08 +0,41%
Nedap N.V. 54,600 +0,20 +0,37%
AEX 878,54 +3,13 +0,36%
Ahold Delhaize 32,050 +0,10 +0,31%
IMCD 144,300 +0,40 +0,28%
ASR Nederland 45,190 +0,11 +0,24%
Kendrion 11,000 0,00 0,00%
PostNL 1,013 0,00 0,00%
Vastned 24,500 0,00 0,00%
Wereldhave 14,060 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Air France-KLM 7,940 -0,93 -10,50%
EBUSCO HOLDING 3,850 -0,44 -10,26%
BAM 4,152 -0,13 -2,99%
ADYEN NV 1.335,800 -40,60 -2,95%
AMG Critical Materials N.V. 15,080 -0,43 -2,77%
ING 14,984 -0,19 -1,28%
Avantium 2,255 -0,02 -1,10%
CM.COM 6,380 -0,07 -1,09%
UNILEVER PLC 54,700 -0,54 -0,98%
NN Group 45,230 -0,37 -0,81%
ForFarmers 3,420 -0,02 -0,73%
OCI 10,735 -0,08 -0,69%
JDE PEET'S 18,780 -0,13 -0,69%
TKH 36,180 -0,24 -0,66%
KPN 3,589 -0,02 -0,64%
DSM FIRMENICH AG 104,750 -0,65 -0,62%
RELX 43,980 -0,16 -0,36%
Wolters Kluwer 160,450 -0,45 -0,28%
CTP 14,520 -0,02 -0,14%
vlag naam koers verschil relatief verschil
AEX 878,54 +3,13 +0,36%
AEX GR 3.439,98 +16,77 +0,49%
Germany40^ 19.438,60 +399,29 +2,10%
FTSE 100 8.140,74 -25,94 -0,32%
EURO50 4.871,57 +60,72 +1,26%
US30^ 43.750,90 0,00 0,00%
Nasd100^ 21.108,60 0,00 0,00%
US500^ 5.977,15 0,00 0,00%
Japan225^ 39.674,50 0,00 0,00%
VD-NEW 15,45 -1,99 -11,41%
#/^ Index indications calculated real time, zie disclaimer